Vandria is a biopharmaceutical spin-off from Amazentis and was incorporated in Switzerland in 2021. The company discovers and develops novel small molecules that can effectively induce mitophagy to treat age-related and chronic diseases. Through a unique drug discovery engine and a dedicated R&D team, we have developed and patented a range of novel small molecules that specifically target muscle tissue and the CNS. Vandria has entered the IND-enabling stage for identified lead candidates that have shown promising results in vitro and in vivo. The following diseases are targeted: CNS: Mild Cognitive Impairment, ALS, PD Muscle: Sporadic Inclusion Body Myositisand Sarcopenia Vandria is currently seeking further investors to complete its Series A round of $15 million of which $7.5 million has been secured.